Non-Alcoholic Steatohepatitis (NASH) Market Projected at $19.07 Billion by 2029 | Strategic Insights and Forecast Data
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Non-Alcoholic Steatohepatitis (NASH) Market Size Changed, over the years?
In recent times, there has been a significant surge in the non-alcoholic steatohepatitis (NASH) market size. The market is projected to expand from $4.5 billion in 2024 to $6.13 billion in 2025, evidencing a compound annual growth rate (CAGR) of 36.1%. The historical growth can be credited to an increasing incidence of NASH, the obesity crisis, greater awareness and diagnoses, changes in dietary habits and lifestyle, and advancements in healthcare infrastructure.
How Much Will the Non-Alcoholic Steatohepatitis (NASH) Market Be Worth in 2029?
The market size for non-alcoholic steatohepatitis (NASH) is forecasted to undergo massive expansion in the coming years. It’s projected to reach a valuation of $19.07 billion by 2029, growing at a compound annual growth rate (CAGR) of 32.8%. The anticipated growth in this period is due to progress in the development of NASH medications, intensification of NASH screening programs, rising healthcare expenses, joint research endeavors, and governmental backing and regulations. Notable trends for the forecast period incorporate an emphasis on lifestyle alterations and educating patients, intensified collaboration in scientific studies, advancements in regulations and pathway designations, and the implementation of artificial intelligence in diagnosing and tracking the disease.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8805&type=smp
Which is the Largest Company in the Non-Alcoholic Steatohepatitis (NASH) Market?
Major companies operating in the non-alcoholic steatohepatitis (NASH) market include NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Cadila Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens.
What Are the Main Market Drivers in the Non-Alcoholic Steatohepatitis (NASH) Industry?
The surge in obesity cases is catalyzing the demand for the non-alcoholic steatohepatitis (NASH) market. Obesity, characterized by abnormal or excessive fat accumulation, is a health risk, and it includes body weight that surpasses the normal or healthy standards for an individual of a particular height. Non-alcoholic fatty liver disease prevalence is increasing in line with the rising obesity pandemic, which could make NASH the top cause of serious liver disease in the upcoming decades, thus propelling the demand for NASH treatment and associated medications. For instance, in March 2024, the World Health Organization (WHO), a UK-based international public health body, reported that about 2.5 billion adults aged 18 and above were deemed overweight in 2022, with 890 million of them battling obesity. Hence, the increase in obesity incidences will fuel the advancement of the non-alcoholic steatohepatitis (NASH) market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=8805&type=smp
How Is the Non-Alcoholic Steatohepatitis (NASH) Market Segments Structured?
The non-alcoholic steatohepatitis (NASH) market covered in this report is segmented –
1) By Type: Solid, Liquid
2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products
3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider
5) By Application: Oral, Parenteral
Subsegments:
1) By Solid: Tablets, Capsules, Other Solid Dosage Forms
2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms
What Strategic Trends Are Transforming the Non-Alcoholic Steatohepatitis (NASH) Market?
Leading firms in the non-alcoholic steatohepatitis (NASH) market are harnessing the potential of thyroid hormone receptor-beta (THR-beta) agonists in order to improve liver metabolism, decrease the accumulation of liver fat, and enhance overall liver performance. THR-beta agonists are substances that specifically trigger the thyroid hormone receptor-beta subtype, a paramount receptor involved in controlling metabolism, growth, and development. For example, the US-based regulatory organization, the Food and Drug Administration, sanctioned the use of Rezdiffra (resmetirom), a THR-beta agonist, in March 2024. Rezdiffra received approval as the initial treatment option for adults suffering from noncirrhotic NASH with moderate to severe liver fibrosis. Rezdiffra exerts its beneficial effects by specifically activating the THR-beta receptor, thereby controlling lipid metabolism and causing a decrease in intrahepatic triglycerides and overall liver fat buildup.
Access The Full Report Here:
Which Global Regions Offer the Highest Growth in the Non-Alcoholic Steatohepatitis (NASH) Market?
North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2024. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8805
This Report Delivers Insight On:
1. How big is the non-alcoholic steatohepatitis (nash) market, and how is it changing globally?
2. Who are the major companies in the non-alcoholic steatohepatitis (nash) market, and how are they performing?
3. What are the key opportunities and risks in the non-alcoholic steatohepatitis (nash) market right now?
4. Which products or customer segments are growing the most in the non-alcoholic steatohepatitis (nash) market?
5. What factors are helping or slowing down the growth of the non-alcoholic steatohepatitis (nash) market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
